Figure 2.

Change in protein C levels and 28-day mortality in PROWESS patients [9]. DrotAA, drotrecogin alfa (activated); N, total number of patients in each group; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.

Vangerow et al. Critical Care 2007 11(Suppl 5):S4   doi:10.1186/cc6155